Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in adults at high risk of viral exposure

Mammen P. Mammen Jr., Pablo Tebas, Joseph Agnes, Mary Giffear, Kimberly A. Kraynyak, Elliott Blackwood, Dinah Amante, Emma L. Reuschel, Mansi Purwar, Aaron Christensen-Quick, Nieman Liu, Viviane M. Andrade, Julie Carter, Gabriella Garufi, Malissa C. Diehl, Albert Sylvester, Matthew P. Morrow, Patrick Pezzoli, Abhijeet J. Kulkarni, Faraz I. Zaidi, Drew Frase, Kevin Liaw, Hedieh Badie, Keiko O. Simon, Trevor R.F. Smith, Stephanie Ramos, Robert Spitz, Robert J. Juba, Jessica Lee, Michael Dallas, Ami Shah Brown, Jacqueline E. Shea, J. Joseph Kim, David B. Weiner, Kate E. Broderick, Jean D. Boyer, Laurent M. Humeau
doi: https://doi.org/10.1101/2021.05.07.21256652
Mammen P. Mammen Jr.
1Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pablo Tebas
3Hospital of the University of Pennsylvania, Philadelphia, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Agnes
1Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary Giffear
1Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kimberly A. Kraynyak
1Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elliott Blackwood
1Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dinah Amante
1Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emma L. Reuschel
2Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, PA, 19104, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mansi Purwar
2Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, PA, 19104, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aaron Christensen-Quick
1Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nieman Liu
1Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Viviane M. Andrade
1Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julie Carter
1Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gabriella Garufi
1Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Malissa C. Diehl
1Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Albert Sylvester
1Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew P. Morrow
1Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Pezzoli
1Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Abhijeet J. Kulkarni
2Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, PA, 19104, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Faraz I. Zaidi
2Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, PA, 19104, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Drew Frase
2Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, PA, 19104, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin Liaw
2Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, PA, 19104, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hedieh Badie
1Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keiko O. Simon
1Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Trevor R.F. Smith
1Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephanie Ramos
1Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Spitz
4ICON GPHS, Hinckley, OH 44233, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert J. Juba
1Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica Lee
1Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Dallas
1Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ami Shah Brown
1Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacqueline E. Shea
1Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Joseph Kim
1Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David B. Weiner
2Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, PA, 19104, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kate E. Broderick
1Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean D. Boyer
1Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurent M. Humeau
1Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: laurent.humeau@inovio.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Vaccines against SARS-CoV-2 are still urgently needed as only 5% of the global population has been vaccinated. Here we report the safety and immunogenicity of a DNA vaccine (INO-4800) targeting the full-length Spike antigen of SARS-CoV-2 when given to adults at high-risk of exposure.

Methods INO-4800 was evaluated in 401 participants randomized at a 3:3:1:1 ratio to receive either INO-4800 (1 mg or 2 mg dose) or placebo (1 or 2 injections) intradermally (ID) followed by electroporation (EP) using CELLECTRA® 2000 at Days 0 and 28. ClinicalTrials.gov Identifier: NCT04642638

Findings The majority of adverse events (AEs) were of Grade 1 and 2 in severity and did not appear to increase in frequency with the second dose. The number of participants experiencing each of the most common AEs did not differ appreciably between the two dosing groups. The geometric mean fold rise (GMFR) of binding and neutralizing antibody levels were statistically significantly greater in the 2.0 mg dose group versus the 1.0 mg dose group. The T cell immune responses measured by the ELISpot assay were also higher in the 2.0 mg dose group compared to the 1.0 mg dose group.

Interpretation INO-4800 at both the 1.0 mg and 2.0 mg doses when administered in a 2-dose regimen appeared to be safe and well-tolerated in all adult ages. However, the comparative immunogenicity analysis favored selection of INO-4800 2.0 mg dose for advancement into a Phase 3 efficacy evaluation.

Funding The trial was funded by the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, (JPEO-CBRND) in coordination with the Office of the Assistant Secretary of Defense for Health Affairs (OASD(HA)) and the Defense Health Agency.

Research in context INO-4800 is among several vaccines being tested against SARS-CoV-2, the virus that causes COVID-19 with the goal of inducing a protective immune response. The DNA vaccine, INO-4800, administered by ID injection followed by electroporation (EP) using the CELLECTRA® 2000 device, induces a balanced immune response that includes engagement of both T cells and B 1-5.

Added value of this study This is the first report of a randomized, blinded, placebo-controlled clinical trial of INO-4800, a DNA vaccine targeting the SARS-CoV-2 Spike antigen delivered ID followed by EP, in adults at high risk of SARS-CoV-2 exposure.

Competing Interest Statement

MPM, GG, MCD, AS, MPM, PP, KOS, HB, TRFS, SR, JL, MD, ASB, JES, JJK, KEN, JDB and LMH are employees of Inovio Pharmaceuticals RS is an employee of ICON GPHS

Clinical Trial

NCT04642638

Clinical Protocols

https://clinicaltrials.gov/ct2/show/NCT04642638

Funding Statement

The US Department of Defense, Joint Program Executive Office provided funding for the Phase 2 segment of the trial

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

WCG, the central IRB, and multiple local IRBs provided ethical approval for the conduct of the clinical research study

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The preliminary COVID19-001 Phase 1 clinical study datasets are subject to access restriction to protect subject confidentiality as the clinical study is still ongoing.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted May 07, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in adults at high risk of viral exposure
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in adults at high risk of viral exposure
Mammen P. Mammen Jr., Pablo Tebas, Joseph Agnes, Mary Giffear, Kimberly A. Kraynyak, Elliott Blackwood, Dinah Amante, Emma L. Reuschel, Mansi Purwar, Aaron Christensen-Quick, Nieman Liu, Viviane M. Andrade, Julie Carter, Gabriella Garufi, Malissa C. Diehl, Albert Sylvester, Matthew P. Morrow, Patrick Pezzoli, Abhijeet J. Kulkarni, Faraz I. Zaidi, Drew Frase, Kevin Liaw, Hedieh Badie, Keiko O. Simon, Trevor R.F. Smith, Stephanie Ramos, Robert Spitz, Robert J. Juba, Jessica Lee, Michael Dallas, Ami Shah Brown, Jacqueline E. Shea, J. Joseph Kim, David B. Weiner, Kate E. Broderick, Jean D. Boyer, Laurent M. Humeau
medRxiv 2021.05.07.21256652; doi: https://doi.org/10.1101/2021.05.07.21256652
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in adults at high risk of viral exposure
Mammen P. Mammen Jr., Pablo Tebas, Joseph Agnes, Mary Giffear, Kimberly A. Kraynyak, Elliott Blackwood, Dinah Amante, Emma L. Reuschel, Mansi Purwar, Aaron Christensen-Quick, Nieman Liu, Viviane M. Andrade, Julie Carter, Gabriella Garufi, Malissa C. Diehl, Albert Sylvester, Matthew P. Morrow, Patrick Pezzoli, Abhijeet J. Kulkarni, Faraz I. Zaidi, Drew Frase, Kevin Liaw, Hedieh Badie, Keiko O. Simon, Trevor R.F. Smith, Stephanie Ramos, Robert Spitz, Robert J. Juba, Jessica Lee, Michael Dallas, Ami Shah Brown, Jacqueline E. Shea, J. Joseph Kim, David B. Weiner, Kate E. Broderick, Jean D. Boyer, Laurent M. Humeau
medRxiv 2021.05.07.21256652; doi: https://doi.org/10.1101/2021.05.07.21256652

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (431)
  • Anesthesia (99)
  • Cardiovascular Medicine (943)
  • Dentistry and Oral Medicine (178)
  • Dermatology (109)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (420)
  • Epidemiology (8971)
  • Forensic Medicine (4)
  • Gastroenterology (418)
  • Genetic and Genomic Medicine (1938)
  • Geriatric Medicine (190)
  • Health Economics (400)
  • Health Informatics (1323)
  • Health Policy (657)
  • Health Systems and Quality Improvement (517)
  • Hematology (212)
  • HIV/AIDS (416)
  • Infectious Diseases (except HIV/AIDS) (10772)
  • Intensive Care and Critical Care Medicine (571)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (221)
  • Neurology (1819)
  • Nursing (108)
  • Nutrition (271)
  • Obstetrics and Gynecology (351)
  • Occupational and Environmental Health (469)
  • Oncology (992)
  • Ophthalmology (296)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (576)
  • Pharmacology and Therapeutics (275)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1892)
  • Public and Global Health (4111)
  • Radiology and Imaging (674)
  • Rehabilitation Medicine and Physical Therapy (364)
  • Respiratory Medicine (548)
  • Rheumatology (224)
  • Sexual and Reproductive Health (190)
  • Sports Medicine (177)
  • Surgery (207)
  • Toxicology (38)
  • Transplantation (109)
  • Urology (80)